Review of the genotoxic properties of chlorpromazine and related phenothiazines

Mutation Research - Reviews in Genetic Toxicology

Volumn 366, Issue 1, 1996, Pages 9-21

  Gocke, Elmar ^a  

^a Preclinical Research   (Switzerland)

Author keywords

Mutagenicity; Photocarcinogenicity; Photomutagenicity; Psychotropic drug; Review; Tranquilizer

Indexed keywords

CHLORPROMAZINE; PHENOTHIAZINE DERIVATIVE;

BACTERIUM; CHROMOSOME ABERRATION; CYTOGENETICS; DROSOPHILA; GENE MUTATION; GENOTOXICITY; HUMAN; NITROSATION; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET IRRADIATION;

BACTERIA (MICROORGANISMS);

EID: 0030272119     PISSN: 01651110     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1110(96)90004-4     Document Type: Article

References (78)

1. Martindale. 30th Edn. Reynolds J.E.F. The Extra Pharmacopoeia. 1993;The Parmaceutical Press, London.
2. IARC Monograph. Evaluation of the carcinogenic risk of chemicals to humans. 40:1986;425 IARC, Lyon.
3. Caccia S., Garattini S. Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin. Pharmacokinet. 18:1990;434-459.
4. Preiss A., Scheutwinkel-Reich M., Stan H.J. The mutagenic nature of tranquillizers used in animal fattening as revealed in the Salmonella/microsome test. Fleischwirtschaft. 63:1983;243-244.
5. Balbi A., Muscettola G., Staiano N., Martirea G., De Lorenzo F. Psychotropic drugs: evaluation of mutagenic effect. Pharmacol. Res. Commun. 12:1980;423-431.
6. Mortelmans K., Haworth S., Lawlor T., Speck W., Tainer B., Zeiger E. Salmonella mutagenicity tests. 2. results from the testing of 270 chemicals. Environ. Mutagen. 8:(Suppl. 7):1986;1-119.
7. Ferguson L.R., Baguley B.C. Verapamil as a co-mutagen in the Salmonella/mammalian microsome mutagenicity test. Mutation Res. 209:1988;57-62.
8. Obaseiki-Ebor E.E., Aberele J.O. The mutagenic activity of chlorpromazine. Mutation Res. 208:1988;33-38.
9. Preiss A.M., Scheutwinkel-Reich M., Fülle I., Grohmann H.G., Stans H.J. Investigation, with the Salmonella/microsome test, of psychopharmaceuticals used in meat production. Mutation Res. 104:1982;333-337.
10. De Flora S., Zanacchi P., Camoirana A., Bennicelli C., Badolati G.S. Genotoxic activity and potency of 135 compounds in the Ames reversion test and in a bacterial DNA-repair test. Mutation Res. 133:1984;161-198.
11. Matter B.E., Graf U., Hu S.T., Jaeger I., Racine R., Suter W., Würgler F.E. Mutagenicity evaluation of thioridazine. Mutation Res. 116:1983;389-398.
12. Cline J.C., McMahon R.E. Detection of chemical mutagens: use of concentration gradient plates in a high capacity screen. Res. Commun. Chem. Pathol. Pharmacol. 16:1977;523-533.
13. Ray V.A., Holden H.E., Ellis J.H., Hyneck M.L. A study of triflupromazine in dominant-lethal, cytogenetic and host-mediated assays. Mutation Res. 18:1973;301-309.
14. Van Schaik N., Graf U. Structure activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of D. melanogaster. Mutation Res. 286:1993;155-163.
15. Rapoport I.A., Filippova L.M., Zhurkov V.S. Investigation of the mutagenic activity of phenothiazines and other drug preparations. Sov. Genet. 7:1971;1042-1049.
16. Yoon J.S., Mason J.M., Valencia R., Woodruff R.C., Zimmering S. Chemical mutagenesis testing in Drosophila. IV. Results of 45 coded compounds tested for the National Toxicology Program. Environ. Mol. Mutagen. 7:1985;349-367.
17. Talukder G. Effects of some drugs of the phenothiazide group on human chromosomes in vitro. Indian J. Med. Res. 63:1975;457-461.
18. Abdullah S., Miller O.J. Effects of drugs on nucleic acid synthesis and cell division in vitro. Dis. Nerv. Syst. 29:1968;829-833.
19. Zhurkov V.S. Investigation of the mutagenic activity of drug preparations and food additives in a culture of human lymphocytes. Sov. Genet. 11:1975;528-530.
20. Green S., Palmer K., Legator M.S. In vitro cytigenetic investigation of calcium cyclamate, cyclohexylamine and triflupromazine. Food Cosm. Toxicol. 8:1970;617-623.
21. Molina L., Rinkus S., Legator M.S. Evaluation of the micronucleus procedure over a 2-year period. Mutation Res. 53:1978;125.
22. Siva Sankar D.V., Geisler A. Mouse leukocyte chromosome system. Effect of chlorpromazine and aspirin. Res. Commun. Chem. Pathol. Pharmacol. 2:1971;477-482.
23. Siva Sankar D.V. Effect of psychotherapeutic agents on breakage of mouse leukocyte chromosomes. Clin. Res. 17:1969;318.
24. Rao K.P., Rao M.S. Effects of fluphenazine hydrochloride on the bone marrow cells of Swiss mice. Mutation Res. 89:1981;237-240.
25. Suryanarayana A., Rita P., Reddy P.P. Cytogenetic effects of trifluperazine in mice. Food. Chem. Toxicol. 25:1987;615-617.
26. Epstein S.S., Arnold E., Andrea J., Bass W., Bishop Y. Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol. 23:1972;288-325.
27. Petersen K.W., Legator M.S. Dominant lethal effects of triflupromazine in hybrid C3DF1/J mice. Mutation Res. 17:1973;87-92.
28. Crossen P.E., Morgan W.E. The effect of chlorpromazine on SCE frequency in human chromosomes: an in vitro and in vivo study. Mutation Res. 172:1982;225-232.
29. Madle S., Obe G., Schroeter H., Herha J., Pietzcker A. Possible mutagenicity of the psychoactive phenothiazine derivative perazine in vivo and in vitro. Hum. Genet. 53:1980;357-361.
30. Speit G., Vogel W. Effect on sister chromatid exchanges of drugs and dyes by intercalation and photoactivation. Mutation Res. 59:1979;223-229.
31. Speit G. Intercalating substances do not induce sister-chromatid exchanges (SCES) in vivo. Mutation Res. 104:1982;261-266.
32. Carlo P., Maura A., Ledda A., Finollo R., Ricci R., Brambilla G. Lack of DNA fragmentation in rats treated with high oral doses of drugs acting on the central nervous system. Arzneim. Forsch. 36:1986;797-800.
33. Gabilondo F., Cobo A., Lisker R. Chromosome abnormalities in patients treated with chlorpromazine and perphenazine. Rev. Invest. Clin. 23:(3):1971;177-180.
34. Nielsen J., Friedrich U., Tsuboi T. Chromosome abnormalities in patients treated with chlorpromazine, perphenazine, and lysergide. Br. Med. J. 3:1969;634-636.
35. Cohen M.M., Lieber E., Schwartz H.N. In vivo cytogenetic effects of perphenazine and chlorpromazine: a negative study. Br. Med. J. 3:1972;21-23.
36. Cohen M.M., Hirschhorn K., Frosch W.A. Cytogenetic effects of tranquillizing drugs in vivo and in vitro. J. Am. Med. Assoc. 207:1969;2425-2426.
37. Gilmour D.G., Bloom A.D., Lele K.P., Robbins E.S., Maximilian C. Chromosomal aberrations in users of psychoactive drugs. Arch. Gen. Psychiatry. 24:1971;268-272.
38. Saxena R., Ahuya Y-R. Clastogenic effect of the psychotropic drug thioridazine on human chromosomes in vivo. Hum. Genet. 62:1982;198-200.
39. Roman I.C. Rat and human chromosome studies after promazine medication. Br. Med. J. 4:1969;172.
40. Waters M.D., Stack H.F., Jackson M.A., Bridges B.A. Hazard identification: efficiency of short-term tests in identifying germ cell mutagens and putative nongenotoxic carcinogens. Environ. Health Perspect. 101:(Suppl. 3):1993;61-72.
41. Adler I.D., Ashby J. The present lack of evidence for unique rodent germ-cell mutagens. Mutation Res. 212:1989;55-66.
42. Tucker J.D., Auletta A., Cimino M.C., Dearfield K.L., Jacobson-Kram D., Tice R.R., Carrano A.V. Sisterchromatid exchange: second report of the Gene-Tox Program. Mutation Res. 297:1993;101-180.
43. Abe S., Sasaki M. SCE as an index of mutagenesis and/or carcinogenesis, in: Sister Chromatid Exchange. Prog. Top. Cytogenet. 2:1982;461-514.
44. MacPhee D.G., Imray F.P. Mutagenesis by photoactivation of chlorpromazine, a tranquillizer of the phenothiazine group. Aust. J. Biol. Sci. 27:1974;231-234.
45. Jose J.G. Photomutagenesis by chlorinated phenothiazin tranquillizers. Proc. Natl. Acad. Sci. USA. 76:1979;469-472.
46. Ben-Hur E., Prager A., Green M., Rosenthal I. PH dependence of the photoxic and photomutagenic effects of chlorpromazine. Chem. Biol. Interact. 29:1980;223-233.
47. Levin D.E., Yamasaki E., Ames B.N. A new Salmonella tester strain, TA97, for the detection of frameshift mutagens. Mutation Res. 94:1982;315-330.
48. Ellenberger J. Mutagenesis by heterocyclic aromtic compounds in Escherichia coli K12 strains of differing repair capacities. Mutation Res. 113:1983;335-336.
49. Henderson L., Fedyk J., Bourner C., Windebank S., Fletscher S., Lovell W. Photomutagenicity assays in bacteria: factors affecting assay design and assessment of photomutagnic potential of para-aminobenzoic acid. Mutagenesis. 9:1994;459-465.
50. De Mol N.J., Posthuma R.M., Mohn G.R. Induction of repairable DNA damage in Escherichia coli and interaction with DNA in vitro by the radical cation of chlorpromazine. Chem. Biol. Interact. 47:1983;223-237.
51. Dean S.W., Lane M., Dunmore R.H., Ruddock S.P, Martin C.N., Kirkland D.J., Loprieno N. Development of assays for the detection of photomutagenicity of chemicals during exposures to UV light. 1. Assay development. Mutagenesis. 6:1991;335-341.
52. Chételat A., Albertini S., Dresp J.H., Strobel R., Gocke E. Photomutagenesis test development: I. 8-Methoxypsoralen, chlorpromazine and sunscreen compounds in bacterial and yeast assays. Mutation Res. 292:1993;241-250.
53. Merville M.P., Calberg-Bacq C.M., Piette J., Decuyper J., van de Vorst A. Phototoxicity of phenothiazine derivatives. 1. Inactivating and mutagenic effects on bacteriophage FX174. Chem. Biol. Interact. 44:1983;261-274.
54. Kelly-Garvert F., Legator M.S. Photoactivation of chlorpromazine: cytogenetic and mutagenic effects. Mutation Res. 21:1973;101-105.
55. Chételat A., Dresp J.H., Gocke E. Photomutagenesis test development: II. 8-Methoxypsoralen, chlorpromazine and sunscreen compounds in chromosomal aberration assays using CHO cells. Mutation Res. 292:1993;251-258.
56. Matsuo I., Ohkido M., Fujita H., Suzuki K. Chlorpromazine photosensitization. 2. failure to detect any evidence for involvement of DNA damage in the photodynamic killing of Escherichia coli in the presence of chlorpromazine. Photochem. Photobiol. 31:1980;175-178.
57. Jose J.G., Yielding K.L. Photosensitive cataractogens, chlorpromazine and methoxypsoralen, cause DNA repair synthesis in lens epithelial cells. Invest. Ophthalmol. Visual Sci. 17:1978;687-691.
58. Peak M.J., Pfaff M., Peraino C. Chlorpromazine recudes UV-induced squamous cell carcinogenesis in hairless mice and enhances UV-induced DNA damage in culture cells. Br. J. Cancer. 60:1989;220-222.
59. Gocke, E. unpublished data.
60. Decuyper J., Piette J., Merville M.P., van de Vorst A. Termini generated at the site of the DNA breakage mediated by photoexcited promazines. Biochem. Pharmacol. 35:1986;1345-1350.
61. Kahn G., Davis B.P. In vitro studies on longwave ultraviolet light dependent reaction of the skin photosensitizer chlorpromazine with nucleic acids, purines and pyrimidines. J. Invest. Dermatol. 55:1970;47.
62. Day R.S. III, Dimattina M. Photodynamic action of chlorpromazine on adenovirus-5: repairable damage and single-strand breaks. Mutation Res. 46:1977;112-113.
63. Day R.S. III, Dimattina M. Photodynamic action of chlorpromazine on adenovirus 5: repairable damage and single-strand breaks. Chem. Biol. Interact. 17:1977;89-97.
64. Oppenländer T. A comprehensive photochemical and photophysical assay exploring the photoreactivity of drugs. Chimia. 42:1988;331-342.
65. Ciulla T.A., Epling G.A., Kochevar I.E. Photoaddition of chlorpromazine to guanosine-5′-monophosphate. Photochem. Photobiol. 43:1986;607-613.
66. Kelly G., Meikle W.D., Moore D.E. Enhancement of UV-induced skin carcinogenesis by azathioprine: Role of photochemical sensitisation. Photochem. Photobiol. 49:1989;59-65.
67. Andrews A.W., Fornwald J.A., Lijinsky W. Nitrosation and mutagnicity of some amine drugs. Toxicol. Appl. Pharmacol. 52:1980;237-244.
68. Takeda Y., Kanaya H. Formation of nitroso compounds and mutagens from tranquillizers by drug/nitrite interaction. Cancer Lett. 12:1981;81-86.
69. Brambilla G., Cajelli E., Finollo R., Maura A., Pino A., Robbiano L. Formation of DNA-damaging nitroso compounds by interaction of drugs with nitrite. A preliminary screening for detecting potentially hazardous drugs. J. Toxicol. Environ. Health. 15:1985;1-24.
70. Calle L.M., Sullivan P.D., Nettleman M.D., Ocasio I.J., Blazyk J., Jollick J. Antioxidants and the mutagenicity of benzo[a]pyrene and some derivatives. Biochem. Biophys. Res. Commun. 85:1978;351-356.
71. Calle L.M., Sullivan P.D. Screening of antioxidants and other compounds for antimutagenic properties towards benzo[a]pyrene-induced mutagenicity in strain TA98 of Salmonella typhimurium. Mutation Res. 101:1982;99-114.
72. Bayless J.H., Jablonski J.E., Roach S.M., Sullivan P.D. Inhibition of the mutagenicity and metabolism of 6-methylbenzo[a]pyrene and 6-hydroxymethylbenzo[a]pyrene. Biochem. Pharmacol. 35:1986;2313-2322.
73. Kittle J.D. Jr., Calle L.M., Sullivan P.D. The effect of substituted phenothiazines on the mutagenicity of benzo[a]pyrene. Mutation Res. 80:1981;259-264.
74. Tosk J. Chlorpromazine protection against acridineinduced reversion of a histidine-requiring mutant of Salmonella thyphimurium. Mutation Res. 24:1974;1-3.
75. Loenn U., Loenn S. Increased growth inhibition and DNA lesions in human colon adenocarcinoma cells treated with methotrexate of 5-fluorodeoxyuridine followed by calmodulin, inhibitiors. Cancer Res. 48:1988;3319-3323.
76. Lialiaris T., Mourelatos D., Dozi-Vassiliades J. Enhancement of cytogenetic damage by chloropromazine in human lymphocytes treated with alkylating antineoplastics and caffeine. Mutation Res. 206:1988;361-365.
77. Lialiaris T., Pantazaki A. Effects of chlorpromazine on the structure of nucleic acids and cytogenetic studies in combination with adriamycin in Ehrlich ascites cells in vivo and/or with caffeine in human lymphocytes in vitro. Mutation Res. 234:1990;396.
78. Lialiaris T., Pantazaki A., Sivridis E., Mourelatos D. Chlorpromazine-induced damage on nucleic acaids: a combined cytogenetic and biochemical study. Mutation Res. 265:(2):1992;155-163.